After obtaining $42 million in a Series B investment round, Aktiia changes its name to Hilo

(London, UK) Hilo formerly Aktiia a blood pressure intelligence platform secured $42 million Series B funding co-led by Earlybird Health and Wellington Partners total funding exceeds $100 million. Funding will accelerate the company's mission to manage global blood pressure product innovation market expansion and enterprise platform development. The company rebranded to Hilo reflecting its global ambition for accessible cuffless clinically validated blood pressure monitoring. Hilo has sold over 120000 devices and developed a machine learning model trained on billions of optical signals and millions of calibration points.

"We are excited to co-lead this financing and to be backing Hilo's innovative technology, which provides groundbreaking advancements to the billions of people with elevated blood pressure today," declared Johannes Fischer, Managing Partner at Wellington Partners. "We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health."

The company achieved CE marking regulatory approvals in Canada Australia and Saudi Arabia 76% annual revenue growth and completed a pivotal clinical trial for US FDA application. Hilo's technology uses a mobile phone camera for blood pressure monitoring. The company's foundation model is built on extensive real-world user data. Hilo aims to provide convenient valuable blood pressure reports for individuals and healthcare professionals. The company has a multidisciplinary team with over 120 publications and 35 patents. Hilo is headquartered in Switzerland and expanding globally. Hilo's system is not for self-diagnosis consultation with healthcare providers is necessary.

SOURCE Aktiia